The hydroxamate family of compounds has been pursued in the development of therapeutics for Huntington’s disease (HD), which is an incurable and progressive neurodegenerative disorder known to be responsive to a reduction in HDAC4 levels [16,20] but has not currently been pursued as a method for glioma therapy. This evidence concerns the gene HDAC4 and glioma.